Everolimus TFOS is a kinase inhibitor indicated in adult and pediatric patients aged one year and older with tuberous ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell carcinoma ...

Researchers evaluated a neoantigen-targeting personalized cancer vaccine in patients with high-risk, fully resected clear ...

Lauren had to learn to walk and use her arms again at 18 after treatment, and a scan has now found the tumour is back 10 ...

A phase 1 study of a personalized cancer vaccine demonstrated antitumor immunity in all treated patients with resected renal ...

Subepithelial lesions (SLEs) are often detected incidentally during endoscopic examination. They represent a heterogeneous ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

DNA testing may inform treatment decisions and predict outcomes of adjuvant chemotherapy in patients with stage II-III colorectal cancer.

Natco Pharma receives FDA approval for Everolimus tablets, launching generic version of Afinitor Disperz in U.S. market.

NATCO Pharma said that it has received approval of its ANDA for Everolimus tablets for oral suspension (TFOS), a generic version of AFINITOR DISPERZ by Novartis Pharmaceutical Corporation.

Natco Pharma has received US FDA approval for its generic version of Everolimus tablets for oral suspension, indicated for ...